VISIT OUR COVID-19 HUB

Our Science
GettyImages-1208505315_790x500_1_0.png
GettyImages-1208505315_1000x450_0_0_0.jpg

VISIT OUR COVID-19 HUB

Sharing resources to stay safe and updates on our efforts we hope could bring an end to the global health crisis.

Doing Better: Increasing Diversity in Clinical Trials

Our Purpose
DemographicDiversityClinicalTrials_380X500_v2.jpg
DemographicDiversityClinicalTrials_1000X450.jpg

Doing Better: Increasing Diversity in Clinical Trials

We’re working to do better. By analyzing our clinical trial data, we are exploring ways to improve representation and reduce health disparities amongst our participants.

The Facts About Pfizer and BioNTech’s COVID-19 Vaccine

Our Science
young_woman_getting_vaccinated_380x500_0.png
young_woman_getting_vaccinated_1000x450_0.jpg

The Facts About Pfizer and BioNTech’s COVID-19 Vaccine

The U.S. FDA authorization of the Pfizer-BioNTech COVID-19 vaccine for emergency use is a significant step forward in our fight against this pandemic.

COMPETITORS WITH A SHARED PURPOSE

Our Purpose
Accumulus_Synergy_790X500_v2.jpg
Accumulus_Synergy_1000X450.jpg

COMPETITORS WITH A SHARED PURPOSE

Accumulus Synergy brings together 10 biopharma companies, including Pfizer, to build a data-sharing platform.

Find a Trial

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Thanking John Young for His Years of Service

Our People
John-Young-Headshot_380X700.png
John-Young-Headshot_1000X450.jpg

Thanking John Young for His Years of Service

Chief Executive Officer Albert Bourla celebrates and thanks Chief Business Officer John Young for his years of service to Pfizer – and to patients.

PFIZER’S COMMITMENT TO PATIENTS REFLECTED IN NEW IP PACT

Our Purpose
IP-Pact tile image mobile
IP-Pact tile image

Latest News

Second-Quarter 2021 Revenues of $19.0 Billion, Reflecting 86% Operational Growth; Excluding BNT162b2 (1) , Revenues Grew 10% Operationally to $11.1 Billion The 10% Operational Growth Excluding BNT162b2 (1) in Second-Quarter 2021 Builds on the 6% Operational Growth Delivered by the Comparable Business in Second-Quarter 2020 Second-Quarter 2021 Reported Diluted EPS (2) of $0.98, Adjusted Diluted EPS (3) of $1.07 Raises Full-Year 2021 Guidance (4) for Revenues to a Range of $78.0 to $80.0 Billion…